AtriCure (NASDAQ:ATRC) Director Sells $138,283.20 in Stock

Key Points

• Director sale: Karen Prange sold 3,564 AtriCure shares at an average price of $38.80, generating $138,283.20 and reducing her holdings by 13.51% to 22,809 shares.
• Business performance: AtriCure reported quarterly earnings of $0.18 per share and revenue of $153.6 million, exceeding the $151.8 million analyst estimate. The company issued fiscal 2026 EPS guidance of $0.24–$0.32.
• Market outlook: Shares recently traded at $40.60, while analysts maintain a consensus “Moderate Buy” rating with a $48.50 price target; institutional investors own 99.11% of the stock.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Karen Prange sold 3,564 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director owned 22,809 shares of the company's stock, valued at $884,989.20. This trade represents a 13.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Karen Prange also recently made the following trade(s):

• On Wednesday, May 20th, Karen Prange sold 3,000 shares of AtriCure stock. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00.

AtriCure Stock Performance

ATRC traded up $1.11 during trading on Friday, reaching $40.60. The company's stock had a trading volume of 108,527 shares, compared to its average volume of 800,970. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company's fifty day moving average price is $31.98 and its 200-day moving average price is $31.31. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $43.18. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 193.54 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the prior year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of AtriCure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oak Harvest Investment Services acquired a new position in AtriCure in the 4th quarter valued at $1,484,000. Massachusetts Financial Services Co. MA lifted its position in AtriCure by 20.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 511,213 shares of the medical device company's stock worth $20,224,000 after buying an additional 86,532 shares during the period. F m Investments LLC acquired a new stake in AtriCure in the 4th quarter worth about $2,872,000. Vanguard Group Inc. increased its stake in shares of AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock valued at $193,993,000 after acquiring an additional 62,861 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of AtriCure in the first quarter worth approximately $7,922,000. Hedge funds and other institutional investors own 99.11% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Zacks Research upgraded shares of AtriCure from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of AtriCure from a "sell (e+)" rating to a "sell (d+)" rating in a research report on Tuesday, July 28th. UBS Group decreased their price target on AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Citigroup restated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source